Efficacy of imatinib dose escalation in Chinese gastrointestinal stromal tumor patients

Table 1 Clinical characteristics of the 52 patients n (%)

Characteristics	Patients
Sex
Male	34 (65.4)
Female	18 (34.6)
Age (yr) (mean ± SD)	53.8 ± 14.0
Primary site
Stomach	18 (34.6)
Small intestine	20 (38.5)
Abdominal cavity	9 (17.3)
Colon	2 (3.8)
Rectum	2 (3.8)
Pelvis	1 (1.9)
Prior surgical resection
Yes	47 (90.4)
No	5 (9.6)
Site of metastasis
Liver	29 (55.8)
Abdominal cavity	31 (59.6)
Pelvis	6 (11.5)
Lung	1 (1.9)
Bone	1 (1.9)
Subcutaneous	1 (1.9)
Prior response to imatinib 400 mg/d
Complete remission	5 (9.6)
Partial remission	27 (51.9)
Stable disease	18 (34.6)
Progressive disease	2 (3.8)
Receiving regional treatment prior to dose escalation
Complete tumor resection	4 (7.7)
Palliative tumor resection	4 (7.7)
Local Radiofrequency ablation treatment	1 (1.9)
No regional treatment	43 (82.7)

Table 2 Hematologic and non-hematologic toxicities of imatinib dose escalation n (%)

	Imatinib 600 mg/d		Imatinib 800 mg/d
	Grade 1-2 (%)	Grade 3-4 (%)	Grade 1-2 (%)	Grade 3-4 (%)
Edema	42 (80.8)	0 (0)	14 (100)	0 (0)
Fatigue	32 (61.5)	1 (1.9)	9 (64.3)	5 (35.7)
Granulocytopenia	19 (36.5)	3 (5.8)	5 (35.7)	1 (7.1)
Skin rash	12 (23.1)	2 (3.8)	7 (50.0)	1 (7.1)
Anemia	7 (13.5)	2 (3.8)	5 (35.7)	0 (0)
Thrombocytopenia	2 (3.8)	0 (0)	1 (7.1)	0 (0)
Anorexia	8 (15.4)	1 (1.9)	6 (42.9)	0 (0)
Nausea	11 (21.2)	1 (1.9)	6 (42.9)	0 (0)
Alopecia	0 (0)	0 (0)	2 (14.3)	0 (0)
Abdominal pain	11 (21.2)	0 (0)	7 (50.0)	0 (0)
Diarrhea	5 (9.6)	0 (0)	1 (7.1)	0 (0)
Epiphora	2 (3.8)	0 (0)	2 (14.3)	0 (0)